Perinatal growth restriction is associated with heightened sympathetic tone and hypertension. We have previously shown that naturally occurring neonatal growth restriction (GR) programs hypertension in male but not female mice. We therefore hypothesized that intact ovarian function or post-ovariectomy estrogen administration protects GR female mice from hypertension. Utilizing a non-interventional model that categorizes mice with weanling weights below the 10(th) percentile as GR, control and GR adult mice were studied at three distinct time points: baseline, post-ovariectomy (OVX), and post-OVX with oral estrogen replacement. OVX elicited hypertension in GR mice that was significantly exacerbated by psychomotor arousal (systolic blood pressure at light to dark transition: control 122+/-2; GR 119+/-2; control-OVX 116+/-3; GR-OVX 126+/-3 mmHg). Estrogen partially normalized the rising blood pressure surge seen in GR-OVX mice (23+/-7% reduction). GR mice had left ventricular hypertrophy, and GR-OVX mice in particular had exaggerated bradycardic responses to sympathetic blockade. For GR mice, a baseline increase in baroreceptor reflex sensitivity and high frequency spectral power support a vagal compensatory mechanism, and that compensation was lost following OVX. For GR mice, the OVX-induced parasympathetic withdrawal was partially restored by estrogen (40+/-25% increase in high frequency spectral power, P<0.05). In conclusion, GR alters cardiac morphology and cardiovascular regulation. The hemodynamic consequences of GR are attenuated in ovarian-sufficient or estrogen replete females. Further investigations are needed to define the role of hormone replacement therapy targeted towards young women with estrogen deficiency and additional cardiovascular risk factors, including perinatal growth restriction, cardiac hypertrophy and morning surge hypertension.
Pharmacology, Toxicology and Pharmaceutical Science
1
3%
Agricultural and Biological Sciences
1
3%
Other
4
11%
Unknown
16
42%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2016.
All research outputs
#31,228,352
of 34,410,315 outputs
Outputs from Clinical Science
#3,186
of 3,415 outputs
Outputs of similar age
#296,724
of 337,312 outputs
Outputs of similar age from Clinical Science
#35
of 41 outputs
Altmetric has tracked 34,410,315 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,415 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,312 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
